Do you use carbopatin + docetaxel in neoadjuvant/adjuvant setting in BRCA 1/2+ triple negative breast cancer?   

With data from the TNT trial showing evidence of clinical benefit of carboplatin + docetaxel in patients with deleterious BRCA1/2 mutations diagnosed with metastatic or locally-rrecurrent TNBC.